

Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma: Updated Waterless Empirical Taste Test and Patient-Reported Outcomes Data From TALisman

Niels WCJ van de Donk¹, Rakesh Popat², Beth Faiman³, Junichiro Yuda⁴, Kihyun Kim⁵, Abel Costa⁶, Alexa Laheij⁷, Richard L Doty⁸, James Omei⁹, Brea Lipe¹⁰, Larysa Sanchez¹¹, Ajai Chari¹², Alexander Lin⁸, Herve Sroussi¹³, Mariana Fernandez¹⁴, Kathleen S Gray¹⁵, Svetlana Gavrilov¹⁶, Gloria Aguilar¹⁷, Kasey Bolyard¹⁶, Jennifer Schultz¹⁸, Keqin Qi¹⁸, Diana Cortes-Selva¹⁹, Jacqueline Fabry¹⁹, Sheri Skerget¹⁹, Jenny Zhang¹⁹, Kelly Kato¹⁶, Christoph Heuck¹⁹, Kelly Hawks¹⁹, Mark Wildgust¹⁶, Lori Parisi¹⁶, Leo Rasche²⁰, Nolan Ngo²¹.

*Nonauthor presenter.

¹Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; ²University College London Hospitals NHS Foundation Trust, London, UK; ³Cleveland Clinic, Cleveland, OH, USA; ⁴National Cancer Center Hospital East, Kashiwa, Japan; ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; ⁶ID or Institute for Research and Education, São Paulo, Brazil; ⁷University of Amsterdam and Vrije Universiteit, and Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; ⁸University of Pennsylvania, Philadelphia, PA, USA; ⁹The Central Nebraska Myeloma Support Group, Grand Island, NE, USA; ¹⁰University of Rochester Medical Center, Rochester, NY, USA; ¹¹Icahn School of Medicine at Mount Sinai, New York, NY, USA; ¹²University of California, San Francisco, San Francisco, CA, USA; ¹³Brigham and Women's Hospital, and Harvard School of Dental Medicine, Boston, MA, USA; ¹⁴Johnson & Johnson, Madrid, Spain; ¹⁵Johnson & Johnson, Bridgewater, NJ, USA; ¹⁶Johnson & Johnson, Raritan, NJ, USA; ¹⁷Johnson & Johnson, Leiden, Netherlands; ¹⁸Johnson & Johnson, Titusville, NJ, USA; ¹⁹Johnson & Johnson, Spring House, PA, USA; ²⁰University Hospital of Würzburg, Würzburg, Germany; ²¹Johnson & Johnson, Dallas-Fort Worth, TX, USA

Key Takeaway

Dysgeusia measured by the objective Waterless Empirical Taste Test (WETT®) rapidly develops after starting talquetamab (Tal) and begins to recover after 3 months, with improvement/resolution in 67% (6/9) of patients who received 7 months of treatment

Conclusions

Severe dysgeusia and dry mouth tend to stabilize or improve by 4–6 cycles per the Scale of Subjective Total Taste Acuity (STTA) and Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)

No improvement of onset, incidence, or severity of dysgeusia was observed with either prophylactic dexamethasone or pregabalin; interpretation limited by small sample size

Onset of dysgeusia coincides with reduction in salivary components associated with taste perception, although data are preliminary

Findings support informed management and expectation setting for patients, caregivers, and healthcare providers, to help maintain clinical benefit of Tal

Acknowledgments
We thank the patients who participated in the study and their families and caregivers, the physicians and nurses who cared for patients and supported this clinical trial, staff members at the study sites, and staff members involved in data collection and analyses. This study was funded by Johnson & Johnson. Medical writing support was provided by Michelle Yang, PharmD, of Eloquent, part of Envision Ignite, an Envision Medical Communications agency, a part of Envision Pharma Group, and funded by Johnson & Johnson. © 2026 European Hematology Association. En. Reused with permission. This abstract was accepted and previously presented at the EHA 2025 Congress. All rights reserved.

Disclosures
NN is an employee and stockholder of Johnson & Johnson.

Introduction

- Tal is the first GPRC5D-targeting bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM), eliciting high response rates and a 3-year overall survival rate of 60.8%,¹⁻⁴ with meaningful improvements in quality of life⁵
- In previously reported results, TALisman (NCT06500884) showed that dysgeusia per WETT was detected as early as 2 weeks, with resolution beginning at the end of 3 months⁶

The ongoing phase 2 TALisman study leverages innovative tools to objectively assess dysgeusia, allowing for better characterization of its onset, severity, and resolution, as well as evaluation of prophylactic interventions⁷

We present dysgeusia data and patient-reported outcomes (PROs) with longer follow-up from the control and prophylactic dexamethasone (Prophy dex) cohorts, and initial data for pregabalin (Prophy pregabalin)

Figure 1: Current tools to assess dysgeusia^{8,9} are limited. WETT is an objective test, comprising taste strips applied sequentially to the tongue to sensitively detect taste changes¹⁰ without relying on subjective reporting


Used with permission. Copyright © 2026 Sensonics International.

CTCAE	STTA	WETT score ^a
- Dysgeusia absent - Grade 1 dysgeusia - Grade 2 dysgeusia	- Grade 0: Same taste - Grade 1: Mild loss - Grade 2: Moderate loss - Grade 3: Severe loss - Grade 4: Complete loss	- Normal: Scores above the 25th percentile - Dysgeusia: Scores at or below the 25th percentile - Severe dysgeusia: Scores at or below the 10th percentile
Subjective	Subjective	Objective
HCP-reported	Patient-reported	Instrument-based

^aPercentiles for dysgeusia used in this study. CTCAE, Common Terminology Criteria for Adverse Events; HCP, healthcare professional.

Results

Figure 2: Baseline characteristics were generally similar across cohorts; median follow-up was 5.8 months for Tal-only, 5.4 months for Prophy dex, and 4.0 months for Prophy pregabalin




References

1. Verkleij CPM, et al. *Blood Adv* 2021;5:2196-215. 2. TALVEY™ (talquetamab-tgvs). Prescribing information. Horsham, PA: Janssen Biotech, Inc.; 2023. 3. European Medicines Agency. TALVEY™ (talquetamab). Accessed April 27, 2026. <https://www.ema.europa.eu/en/medicines/human/EPAR/talvey>. 4. Rasche L, et al. Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: 3-Year Follow-Up of the Phase 1/2 MonumentTAL-1 Study. *Blood*. In progress. 5. Schinke C, et al. *Cancer* 2025;131:e35927. 6. Popat R, et al. Presented at ASH; December 6–9, 2025; Orlando, FL, USA. Poster #5821. 7. ClinicalTrials.gov identifier. NCT06500884. Accessed October 31, 2025. <https://www.clinicaltrials.gov/study/NCT06500884>. 8. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. National Cancer Institute, 2023. Available from: [https://www.ctc.ucl.ac.uk/TrialDocuments/Uploaded/Common%20Criteria%20for%20Adverse%20Events%20\(CTCAE\)%20v5.0_14092023_0.pdf](https://www.ctc.ucl.ac.uk/TrialDocuments/Uploaded/Common%20Criteria%20for%20Adverse%20Events%20(CTCAE)%20v5.0_14092023_0.pdf). 9. The Scale of Subjective Total Taste Acuity (STTA). In: Taste Acuity – An Overview. ScienceDirect Topics. 2022. Available from: <https://www.sciencedirect.com/topics/medicine-and-dentistry/taste-disorder>. Accessed May 1, 2026. 10. Doty RL, et al. *Behav Res Methods* 2021;53:864-73.

Methods

TALisman phase 2 study design




^aIncluding a proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody. ^bECOG PS of 2 or 3 permitted once physical limitations not related to MM or associated therapy are stable. ^cTo accommodate prophylaxes being available at different times. ^dA control cohort was enrolled concurrently with each cohort B–F. ^ePatients receive prophylaxis starting 7 days (1 day for tacrolimus) before talquetamab step-up doses (C1D1) followed by talquetamab 0.8 mg/kg SC Q2W. ^fProphylactic dexamethasone oral rinse: swish and hold 5 mL for 2–3 minutes 2–4 times a day. Low-dose antifungal drugs or standard of care could be used to prevent thrush. ^gDuration of treatment is 24 months. ^hFutility analyses for cohorts B–E will determine termination or continuation of each prophylaxis cohort. ⁱResolution/improvement is defined as either dysgeusia downgraded to no dysgeusia or severe dysgeusia downgraded to nonsevere dysgeusia per WETT. ^jSaliva samples are collected during stimulated and unstimulated flow conditions to assess potential changes in composition over time. MUC5B and amylase measurements were determined using enzyme-linked immunosorbent assay (ELISA)-based assays. ^kOnly 1 collection during the period. BID, twice a day; C, cycle; D, day; ECOG PS, Eastern Cooperative Oncology Group performance status; MM, multiple myeloma; MUC5B, mucin 5B; ODT, orally disintegrating tablet; Q2W, every other week; Q4W, every 4 weeks; Q8W, every 8 weeks; SC, subcutaneous.

Table: Across cohorts, most patients experienced dysgeusia per WETT. Median time to severe dysgeusia was longer than median time to dysgeusia

	Tal-only (N=19)	Prophy dex (N=15)	Prophy pregabalin (N=16)
Patients with dysgeusia, n (%)	16 (84.2)	13 (86.7)	16 (100.0)
Patients with severe dysgeusia, n (%)	12 (63.2)	13 (86.7)	16 (100.0)
Median time to dysgeusia, days (95% CI)	11.9 (6.1–28.0)	7.9 (3.0–24.0)	10.0 (4.0–21.9)
Median time to severe dysgeusia, days (95% CI)	67.9 ^a (7.9–NR)	9.1 (4.9–28.9)	16.4 (7.9–32.9)

^a3 patients in the Tal-only cohort had onset of severe dysgeusia during cycle 3 (median time to severe dysgeusia, 75 days [range, 68–99]), 1 of 3 patients received repeat step-up dosing.

Figure 3: Dysgeusia per WETT resolved/improved in 10 of 15 patients by the end of month 3 and in 3 of 4 in the Tal-only group by the end of month 7. Dysgeusia per WETT resolved/improved in 6 of 9 patients by the end of month 7. Prophy dex and pregabalin did not improve dysgeusia outcomes vs Tal-only control



Dysgeusia, skin adverse events (AEs), infections, xerostomia, and neutropenia were among the most common AEs in the Tal-only cohort (not shown). No patients discontinued Tal due to AEs. 63.2% had dose modifications of Tal

Figure 4: Per subjective STTA, overall severity of taste loss was greatest across cycles 4–5 and then began to recover. Per PRO-CTCAE, plateauing trends were observed for severe dysgeusia after cycle 4 and severe dry mouth after cycle 6 (not shown). Low numbers in later cycles limit definitive conclusions





Figure 5: Reduced salivary MUC5B (a gel-forming mucin associated with taste perception) and a trend toward reduced salivary amylase was observed between cycles 1 and 3, consistent with the onset of dysgeusia



Multiple Myeloma